Lead Product(s): FOR-6219
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: FOR-6219
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 03, 2021
The successfully concluded Phase 1 program demonstrated that FOR-6219, a HSD17B1 enzyme-targeting small-molecule, was safe and well-tolerated and delivered additional results supporting Forendo’s therapeutic concept.